DE69022876D1 - Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe. - Google Patents

Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe.

Info

Publication number
DE69022876D1
DE69022876D1 DE69022876T DE69022876T DE69022876D1 DE 69022876 D1 DE69022876 D1 DE 69022876D1 DE 69022876 T DE69022876 T DE 69022876T DE 69022876 T DE69022876 T DE 69022876T DE 69022876 D1 DE69022876 D1 DE 69022876D1
Authority
DE
Germany
Prior art keywords
drug
delayed
formulations
coated
release particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69022876T
Other languages
English (en)
Other versions
DE69022876T2 (de
DE69022876T3 (de
Inventor
George N Paradissis
James A Garegnani
Roy S Whaley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kv Pharmaceutical Co
Original Assignee
Kv Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26996237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69022876(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/349,533 external-priority patent/US5122384A/en
Application filed by Kv Pharmaceutical Co filed Critical Kv Pharmaceutical Co
Application granted granted Critical
Publication of DE69022876D1 publication Critical patent/DE69022876D1/de
Publication of DE69022876T2 publication Critical patent/DE69022876T2/de
Publication of DE69022876T3 publication Critical patent/DE69022876T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
DE69022876T 1989-05-05 1990-05-04 Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe. Expired - Lifetime DE69022876T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/349,533 US5122384A (en) 1989-05-05 1989-05-05 Oral once-per-day organic nitrate formulation which does not induce tolerance
US07/469,210 US5133974A (en) 1989-05-05 1990-01-24 Extended release pharmaceutical formulations

Publications (3)

Publication Number Publication Date
DE69022876D1 true DE69022876D1 (de) 1995-11-16
DE69022876T2 DE69022876T2 (de) 1996-05-02
DE69022876T3 DE69022876T3 (de) 1999-06-17

Family

ID=26996237

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69022876T Expired - Lifetime DE69022876T3 (de) 1989-05-05 1990-05-04 Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe.

Country Status (7)

Country Link
US (2) US5133974A (de)
EP (1) EP0396425B2 (de)
AT (1) ATE128863T1 (de)
AU (1) AU635021B2 (de)
CA (1) CA2016039C (de)
DE (1) DE69022876T3 (de)
ES (1) ES2080796T5 (de)

Families Citing this family (613)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
ES2064564T3 (es) * 1989-09-21 1995-02-01 American Cyanamid Co Sistema de liberacion pulsatil de dosis unitaria diaria de minociclina.
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
IT1252185B (it) * 1991-12-11 1995-06-05 Therapicon Srl Preparazioni farmaceutiche a liberazione programmata
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
NO924985L (no) * 1991-12-30 1993-07-01 Akzo Nv Thyroaktiv blanding med vedvarende frigjoering
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
WO1993017673A1 (en) * 1992-03-03 1993-09-16 Top Gold Pty., Limited Sustained release analgesics
GB2267219B (en) * 1992-05-28 1996-04-03 Elan Corp Plc Differential release tablet with multiple active agents
DK0656881T3 (da) * 1992-07-30 1999-06-23 Cal Int Ltd Ester og kombinationer af et organisk nitrat og et salicylat
US5422122A (en) * 1992-08-04 1995-06-06 Eurand America, Incorporated Controlled release potassium chloride tablet
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
JPH09500645A (ja) * 1993-07-22 1997-01-21 ワーナー−ランバート・コンパニー 制御放出タクリン薬物送達システムおよびその製造方法
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
JP2716361B2 (ja) * 1994-02-16 1998-02-18 株式会社アドバンス 生体用プリント電極
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US7060293B1 (en) 1994-05-25 2006-06-13 Purdue Pharma Powder-layered oral dosage forms
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
GB9503492D0 (en) * 1995-02-22 1995-04-12 Ed Geistlich S Hne A G F R Che Chemical product
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
AU6122496A (en) * 1995-06-20 1997-01-22 Pharma-Vinci A/S A method of preparing an oral preparation provided on the outer side with an enteric coating, as well as an oral preparation obtained by the method
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
PL186605B1 (pl) * 1995-09-21 2004-01-30 Pharma Pass Llc Tabletka lub mikrotabletka zawierająca rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol oraz sposób wytwarzania tabletek lub mikrotabletek zawierających rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US20060068000A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
WO1998001117A1 (en) * 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
IT1283478B1 (it) * 1996-07-22 1998-04-21 Roberto Valducci Composizioni per integrazione nutrizionale comprendenti vitamine idrosolubili a rilascio prolungato
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
EP0951278A2 (de) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Minitablette formulierung zur verzögerte freigabe von cisapride
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
FR2760190B1 (fr) * 1997-02-28 1999-04-09 Adir Composition pharmaceutique pour la liberation programmee de dexfenfluramine
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
PT1009387E (pt) 1997-07-02 2006-08-31 Euro Celtique Sa Formulacoes estabilizadas de libertacao controlada de tramadol
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
FR2774910B1 (fr) 1998-02-16 2001-09-07 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US6197347B1 (en) 1998-06-29 2001-03-06 Andrx Pharmaceuticals, Inc. Oral dosage for the controlled release of analgesic
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6368625B1 (en) * 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US6126967A (en) * 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US6254891B1 (en) * 1998-09-03 2001-07-03 Ascent Pediatrics, Inc. Extended release acetaminophen
JP2000109341A (ja) * 1998-10-01 2000-04-18 Jsr Corp 無機粒子含有組成物、転写フィルムおよびプラズマディスプレイパネルの製造方法
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
KR20010082251A (ko) * 1998-10-26 2001-08-29 찌바따 이찌로, 다나까 도시오 서방성 입자
JP4613275B2 (ja) * 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド 多粒子改質放出組成物
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
CA2351347A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
PL349501A1 (en) * 1998-12-24 2002-07-29 Janssen Pharmaceutica Nv Controlled release galantamine composition
JP2002536966A (ja) 1998-12-30 2002-11-05 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド カルシウムチャネルファミリーの特徴付け
US6274162B1 (en) 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
EP1591437B1 (de) 1999-05-14 2009-11-25 Nereus Pharmaceuticals, Inc. Interleukin-1 und Tumornekrosefaktor-alpha Modulatoren,Synthese dieser Modulatoren und Methoden zur Anwendung dieser Modulatoren
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
FR2794646B1 (fr) 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
ATE479441T1 (de) 1999-09-03 2010-09-15 Brigham & Womens Hospital Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
EP1228125A4 (de) * 1999-09-14 2009-09-02 Smithkline Beecham Corp Verfahren zur herstellung wässrig überzogener kügelchen
AU762291B2 (en) * 1999-09-30 2003-06-19 Penwest Pharmaceutical Co. Sustained release matrix systems for highly soluble drugs
EP2295043A1 (de) 1999-10-29 2011-03-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US20040171107A1 (en) * 2000-02-23 2004-09-02 David Nelson Modified flourescent proteins
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
CA2400818C (en) 2000-02-24 2009-01-06 Advancis Pharmaceutical Corporation Antibiotic and antifungal compositions
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6623758B2 (en) 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
AU2001253597A1 (en) * 2000-04-12 2001-10-30 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
AU7013401A (en) 2000-06-22 2002-01-02 Univ Iowa Res Found Methods for enhancing antibody-induced cell lysis and treating cancer
DE10033023A1 (de) * 2000-07-07 2002-01-31 Biogrund Gmbh Filmüberzugszusammensetzung auf Basis von Zellulosederivaten und Zuckeralkoholen
US6855721B1 (en) 2000-07-28 2005-02-15 Indevus Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
DE60110814D1 (de) * 2000-08-10 2005-06-16 Jds Pharmaceuticals Llc Zusammensetzungen mit langsamer freigabe enthaltend lithium-carbonat
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
EP1330236A2 (de) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Amoxicillinhaltige arzneizusammensetzungen
US7105174B2 (en) * 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
JP4395549B2 (ja) * 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬物及び発酵生成物の発見のための海洋放線菌分類群
ATE481640T1 (de) * 2000-11-27 2010-10-15 Minerva Biotechnologies Corp Diagnostika, drogenscreening und behandlung für krebs
WO2005019269A2 (en) 2002-11-27 2005-03-03 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
ES2307568T3 (es) * 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US6706274B2 (en) * 2001-01-18 2004-03-16 Scimed Life Systems, Inc. Differential delivery of nitric oxide
ITMI20010220A1 (it) 2001-02-05 2002-08-05 Valpharma Sa Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
CA2440588C (en) * 2001-03-13 2010-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
CA2449175A1 (en) 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
SI1446162T1 (sl) 2001-08-17 2009-04-30 Coley Pharm Gmbh Kombinacija zaporedja imunostimulatornih oligonukleotidov z izboljšano aktivnostjo
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
DK1455593T3 (da) 2001-10-06 2013-08-26 Merial Ltd Fremgangsmåder og sammensætninger til fremme af vækst og medfødt immunitet hos unge dyr
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US6780437B2 (en) * 2001-10-23 2004-08-24 Upsher-Smith Laboratories, Inc. Coated potassium chloride granules and tablets
US20030125292A1 (en) * 2001-11-07 2003-07-03 Sean Semple Mucoscal vaccine and methods for using the same
US6821532B2 (en) * 2001-11-16 2004-11-23 Unitel Technologies, Inc. Methods and compositions for the treatment of benign prostatic hypertrophy
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US20050025824A1 (en) * 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
KR20030056474A (ko) * 2001-12-28 2003-07-04 한국유나이티드제약 주식회사 카르비도파/레보도파 서방정의 조성물과 그의 제조방법
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
EP1492511B3 (de) 2002-04-09 2012-05-02 Flamel Technologies Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
IL164221A0 (en) * 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
US6958161B2 (en) * 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
DE60323482D1 (de) * 2002-05-06 2008-10-23 Massachusetts Inst Technology Diffusionskontrollierte arzneiform sowie herstellungsmethode mittels dreidimensionalem drucken
HUE027779T2 (en) 2002-05-09 2016-11-28 Brigham & Womens Hospital Inc 1L1RL-1 is a marker of cardiovascular disease
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
ATE376854T1 (de) * 2002-06-26 2007-11-15 Alza Corp Minimal nachgiebiger volumen-effizienter kolben für osmotische medikamentenabgabesysteme
IL165910A0 (en) * 2002-07-03 2006-01-15 Pericor Science Inc Compositions of hyaluronic acid and methods of use
PA8578501A1 (es) * 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
WO2004034970A2 (en) * 2002-09-27 2004-04-29 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US20030049698A1 (en) * 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
DK1572217T3 (da) * 2002-12-12 2008-12-15 Nycomed Gmbh Kombinationsmedikament af R,R-formoterol og ciclesonid
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
CL2003002653A1 (es) * 2002-12-18 2005-04-22 Wyeth Corp Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006523613A (ja) * 2002-12-20 2006-10-19 エスティ．ジェイムス アソシエイト エルエルシー／フェイバー リサーチ シリーズ 徐放性医薬投与のための被覆粒子
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
SI2325302T1 (sl) 2003-02-11 2016-05-31 Shire Human Genetic Therapies, Inc. Celice, ki soizražajo sulfatazo in c-formilglicin generirajoči encim ter postopki in uporabe le-teh
WO2004078943A2 (en) * 2003-03-04 2004-09-16 California Institute Of Technology Alternative heterocycles for dna recognition
DE10311585A1 (de) * 2003-03-14 2004-09-23 Basf Ag Wirkstoffhaltige Adsorbate
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
CA2534816A1 (en) 2003-06-12 2004-12-23 Evan Newell Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
NZ544858A (en) * 2003-06-20 2009-07-31 Univ California Salinosporamides and methods for use thereof
MXPA05013982A (es) * 2003-06-20 2006-05-25 Nereus Pharmaceuticals Inc Metodos para utilizar compuestos {3.2.0} heterociclicos y sus analogos.
EP2112920B1 (de) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
US8313775B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
US8313776B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005009364A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
EP1653925A1 (de) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robustes pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005016317A1 (en) * 2003-08-19 2005-02-24 Themis Laboratories Private Limited Process for manufacture of extended release pellets containing diltiazem hci
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
JP2007513869A (ja) 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
DK1670482T4 (da) * 2003-09-16 2022-08-22 Covis Pharma B V Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
WO2005027878A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Delayed released dosage forms
US20050118267A1 (en) * 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
WO2005034979A2 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
JP2007510733A (ja) * 2003-11-05 2007-04-26 サンタラス インコーポレイティッド プロトンポンプ阻害剤および睡眠剤の併用
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005060610A2 (en) * 2003-12-11 2005-07-07 The Trustees Of Columbia University In The City Ofnew York Nano-sized particles, processes of making, compositions and uses thereof
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050281875A1 (en) * 2003-12-17 2005-12-22 Sovereign Pharmaceuticals, Ltd. Promethazine containing dosage form
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
EP2248895B8 (de) 2003-12-19 2016-09-21 Autotelic LLC Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert
US7452730B2 (en) * 2004-01-16 2008-11-18 California Institute Of Technology DNA-binding polymers
ATE509018T1 (de) * 2004-01-23 2011-05-15 Nereus Pharmaceuticals Inc Als antimikrobielle mittel geeignete bisindolpyrrole
EP1568383A3 (de) 2004-02-27 2005-11-16 Antisense Pharma GmbH Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung
US20070155685A1 (en) * 2004-02-27 2007-07-05 Karl-Hermann Schlingensiepen Pharmaceutical composition
JP2007524698A (ja) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト シクレソニドとグリコピロニウムとの組合せ物
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
EP1737473A4 (de) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Lithium-kombinationen und relevante verwendungen
CA2563556C (en) * 2004-04-20 2013-01-29 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
PL1745075T3 (pl) 2004-04-21 2013-09-30 Brigham & Womens Hospital Inc Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US7429617B2 (en) * 2004-04-27 2008-09-30 Medicinova, Inc. Phenoxyalkycarboxylic acid derivatives in the treatment of interstitial cystitis
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
JP2007535559A (ja) 2004-04-30 2007-12-06 ネレアス ファーマシューティカルズ インコーポレイテッド ［３．２．０］複素環式化合物及びその使用法
JP4277904B2 (ja) * 2004-04-30 2009-06-10 アステラス製薬株式会社 経口投与用時限放出型粒子状医薬組成物及び該組成物を含有する口腔内速崩壊錠
CN1968697B (zh) * 2004-05-14 2012-05-16 株式会社绿十字 右旋吗啡喃的神经保护特性
PT1751087E (pt) * 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
WO2006009602A2 (en) 2004-06-16 2006-01-26 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
RS51527B2 (sr) * 2004-08-13 2018-02-28 Boehringer Ingelheim Int Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so, postupak za proizvodnju iste i njena primena
CN101849920A (zh) * 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US7893034B2 (en) * 2004-09-02 2011-02-22 Yale University Regulation of oncogenes by microRNAs
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
WO2007053135A1 (en) * 2004-09-14 2007-05-10 Minerva Biotechnologies Corporation Methods for diagnosis and treatment of cancer
US20060062811A1 (en) * 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2006052991A2 (en) 2004-11-11 2006-05-18 The General Hosptial Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
AU2005311709B2 (en) 2004-12-03 2011-07-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplastic diseases
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
JP2008523097A (ja) * 2004-12-09 2008-07-03 セルジーン・コーポレーション Ｄ−トレオメチルフェニデートを用いた治療
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
FR2882259A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
EP1850835A1 (de) * 2005-02-21 2007-11-07 Flamel Technologies Orale pharmazeutische form von losartan
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
EP1875244B1 (de) * 2005-03-30 2019-01-23 Minerva Biotechnologies Corporation Proliferation muc1 exprimierender zellen
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
EA200702221A1 (ru) * 2005-04-12 2008-04-28 Элан Фарма Интернэшнл Лимитед Композиции с контролируемым высвобождением для лечения бактериальной инфекции, содержащие цефалоспорин
CN101448517A (zh) 2005-04-19 2009-06-03 伊莱利利公司 用于疾病免疫干预的单价和多价合成多糖抗原
US20060241076A1 (en) * 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
DE602006004578D1 (de) 2005-05-05 2009-02-12 Antisense Pharma Gmbh Verwendung von tgf-beta2 antisense oligonukleotiden
US20060257473A1 (en) * 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
KR101502920B1 (ko) 2005-06-21 2015-03-17 조마 (유에스) 엘엘씨 ＩＬ-１β 결합성 항체 및 그의 단편
US8354384B2 (en) * 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
US20070148238A1 (en) * 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
EP2311795A3 (de) 2005-07-21 2011-12-28 Nereus Pharmaceuticals, Inc. Interleukin-1- und Tumornekrosefaktor-Alpha-Modulatoren, Synthese solcher Modulatoren und Verfahren unter Anwendung solcher Modulatoren
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
EP1957093B1 (de) 2005-08-29 2017-04-12 SHASHOUA, Victor E. Neuroprotektive und neurorestorative verfahren und zusammensetzungen
CA2616416A1 (en) * 2005-09-09 2007-05-03 Labopharm, Inc. Trazodone composition for once a day adminisitiation
US20070098796A1 (en) 2005-10-31 2007-05-03 Rekhi Gurvinder S Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride
US20070098791A1 (en) * 2005-10-31 2007-05-03 Rekhi Gurvinder S Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
DK1957647T3 (en) 2005-11-25 2015-04-07 Zoetis Belgium S A Immunostimulatory oligoribonucleotides
US8022054B2 (en) 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
CA2631643C (en) * 2005-12-05 2015-07-07 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
JP2009526021A (ja) * 2006-02-10 2009-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 放出を加減した製剤
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
CN101453993A (zh) 2006-04-03 2009-06-10 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
WO2007120638A2 (en) * 2006-04-12 2007-10-25 President And Fellows Of Harvard College Methods and compositions for modulating glycosylation
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
CN102675136B (zh) * 2006-04-28 2016-01-20 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
CN101453982B (zh) 2006-05-30 2011-05-04 精达制药公司 两件式内部通道渗透递送系统流动调节器
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
AU2007254826B2 (en) * 2006-06-01 2013-10-24 Merck Sharp & Dohme Corp. Pharmaceutical compositions for sustained release of phenyephrine
CN101472561A (zh) * 2006-06-01 2009-07-01 先灵公司 去氧肾上腺素脉冲释放制剂和药物组合物
SG172664A1 (en) * 2006-06-01 2011-07-28 Schering Plough Healthcare Phenylephrine pharmaceutical formulations and compositions for colonic absorption
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
CN101472610A (zh) 2006-06-20 2009-07-01 特朗斯吉有限公司 重组病毒疫苗
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
WO2008147426A2 (en) * 2006-10-04 2008-12-04 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
US20090297626A1 (en) * 2006-11-03 2009-12-03 The Trustees Of Columbia University In The City Of New York Methods for preparing metal oxides
MX2009001711A (es) 2006-11-17 2009-05-08 Supernus Pharmaceuticals Inc Formulaciones de liberacion sostenida de topiramato.
EP2091515B1 (de) * 2006-11-21 2014-06-04 McNeil-PPC, Inc. Analgetische suspensionen mit modifizierter freisetzung
CN101621931A (zh) 2006-11-27 2010-01-06 H.隆德贝克有限公司 杂芳基酰胺衍生物
EP2101735A2 (de) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoteilchenförmige formulierungen und verfahren zur herstellung und verwendung
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
US7829592B2 (en) * 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
US20080152709A1 (en) * 2006-12-22 2008-06-26 Drugtech Corporation Clonidine composition and method of use
WO2008086529A2 (en) * 2007-01-11 2008-07-17 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US20080187579A1 (en) * 2007-02-01 2008-08-07 Pavan Bhat Extended-release dosage form
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
WO2008112388A1 (en) 2007-03-14 2008-09-18 Drugtech Corporation Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
WO2008116216A1 (en) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
MX351611B (es) 2007-03-29 2017-10-20 Wyeth Llc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
DK2139890T3 (da) 2007-03-29 2014-08-25 Wyeth Llc Perifere opioidreceptor-antagonister og anvendelser deraf
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
ES2466672T3 (es) 2007-04-02 2014-06-10 Theracos, Inc. Derivados de glicósido bencílico y métodos de uso
EP2066309B1 (de) 2007-04-04 2012-08-29 Sigmoid Pharma Limited Orale pharmazeutische zusammensetzung
SI2644205T1 (sl) 2007-04-12 2018-11-30 The Brigham And Women's Hospital, Inc. Ciljanje ABCB5 za zdravljenje raka
US20100179158A1 (en) * 2007-04-20 2010-07-15 Hoffman Charles S Inhibitors of cyclic amp phosphodiesterases
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
EP2586428B1 (de) 2007-04-26 2023-11-08 Sublimity Therapeutics Limited Herstellung mehrerer Minikapseln
EP2152304B1 (de) 2007-05-02 2018-08-22 The Regents of the University of Michigan Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
US20100285041A1 (en) * 2007-05-17 2010-11-11 Eugen Uhlmann Class A Oligonucleotides with Immunostimulatory Potency
CN101848706A (zh) * 2007-06-01 2010-09-29 先灵-普劳健康护理产品公司 包含底物和含活性成分和聚乙烯醇的包衣的药用组合物
MX2009013384A (es) * 2007-06-08 2010-01-25 Addrenex Pharmaceuticals Inc Formulacion de liberacion extendida, y metodo para tratar disregulacion adrenergica.
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
UA97971C2 (ru) * 2007-06-08 2012-04-10 Берингер Ингельхайм Интернациональ Гмбх Препарат невирапина пролонгированного высвобождения
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US8524444B2 (en) * 2007-06-15 2013-09-03 President And Fellows Of Harvard College Methods and compositions for detections and modulating O-glycosylation
WO2009002456A2 (en) * 2007-06-21 2008-12-31 Massachusetts Institute Of Technology Methods and compositions relating to progenitor cells
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
WO2009022215A1 (en) 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
JP4809931B2 (ja) 2007-08-23 2011-11-09 セラコス・インコーポレイテッド ベンジルベンゼン誘導体およびその使用方法
CN104069088A (zh) 2007-10-12 2014-10-01 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
RU2469718C2 (ru) * 2007-10-16 2012-12-20 Лабофарм Инк. Двухслойная композиция для непрерывного высвобождения ацетаминофена и трамадола
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
JP5651818B2 (ja) 2007-12-17 2015-01-14 パラディン ラブス インコーポレーテッド 誤用を防止するための放出制御製剤
PL2391650T3 (pl) 2007-12-20 2015-03-31 Xoma Us Llc Sposoby leczenia dny
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin
EP2240022B1 (de) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Oxycodone und Promethazine enthaltende zweischichtige Tabletten
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
WO2009111375A2 (en) * 2008-03-01 2009-09-11 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
EP2385370A1 (de) 2008-04-10 2011-11-09 Massachusetts Institute of Technology (MIT) Verfahren zur Erkennung und Verwendung von auf Krebsstammzellen abzielenden Mitteln
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
US20110076296A1 (en) 2008-04-25 2011-03-31 Innate Pharma S.A. TLR3 Agonist Compositions
CN102076853A (zh) * 2008-05-07 2011-05-25 阿布拉西斯生物科学有限责任公司 通过miRNA增强药物疗法
WO2009137827A2 (en) * 2008-05-09 2009-11-12 Tiara Pharmaceuticals, Inc. Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
JP2011519975A (ja) * 2008-05-12 2011-07-14 ネレアス ファーマシューティカルズ インコーポレイテッド プロテアソーム阻害剤としてのサリノスポラミド誘導体
EP2303888B1 (de) 2008-06-12 2015-05-06 President and Fellows of Harvard College Verbindungen für antimikrobielle eingriffe
EP2312944B1 (de) 2008-07-15 2018-09-05 Theracos, Inc. Deuterierte benzylbenzolderivate und verwendungsverfahren
CA2737146A1 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
WO2010019915A1 (en) * 2008-08-15 2010-02-18 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
JP5749168B2 (ja) 2008-08-22 2015-07-15 セラコス・インコーポレイテッドＴｈｅｒａｃｏｓ， Ｉｎｃ． Ｓｇｌｔ２阻害剤の製造方法
US20110092493A1 (en) * 2008-09-24 2011-04-21 Clark Levi Dose-controlled transdermal promethazine compositions and methods of use
EP2349209A2 (de) * 2008-09-26 2011-08-03 Nanobio Corporation Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
CA2738414C (en) * 2008-09-29 2014-05-27 Wockhardt Research Centre Extended release dosage form of ropinirole
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
KR20110069144A (ko) 2008-10-09 2011-06-22 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
WO2010047775A2 (en) * 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
EP3734281A3 (de) 2008-11-14 2021-01-27 The Brigham and Women's Hospital, Inc. Therapeutische und diagnostische verfahren im zusammenhang mit krebsstammzellen
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
PL2358360T3 (pl) 2008-11-18 2017-02-28 Ucb Biopharma Sprl Preparaty o przedłużonym uwalnianiu zawierające pochodną 2-okso-1-pirolidyny
JP5930278B2 (ja) 2008-11-25 2016-06-08 ユニバーシティー オブ ロチェスター Ｍｌｋ阻害剤および使用方法
US8486449B2 (en) 2008-12-16 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
US20100260677A1 (en) 2009-03-02 2010-10-14 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
CA2760689A1 (en) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
EP2424363A1 (de) * 2009-05-01 2012-03-07 Atley Pharmaceuticals, Inc. Zusammensetzungen mit einem antihistaminikum, hustenlindernden und abschwellenden mittel mit retard-formulierung
SI2992899T1 (sl) 2009-05-14 2020-10-30 Bayer Intellectual Property Gmbh Povečan imunski odziv pri ptičjih vrstah
SI2432455T1 (sl) 2009-05-18 2015-04-30 Sigmoid Pharma Limited Sestava, obsegajoäśa oljne kapljice
JP2012528858A (ja) 2009-06-01 2012-11-15 プレジデント アンド フェロウズ オブ ハーバード カレッジ Ｏ−ＧｌｃＮＡｃ転移酵素阻害剤およびその使用
US20100316673A1 (en) 2009-06-16 2010-12-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
WO2011011092A1 (en) 2009-07-22 2011-01-27 University Of Massachusetts Methods and compositions to reduce oxidative stress
KR20120107456A (ko) 2009-07-30 2012-10-02 안티센스 파마 게엠베하 화학요법제와 티지에프-베타 시스템의 억제제의 조합
EP2464341B1 (de) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunmodulatorische zusammensetzungen mit einer polymermatrix und einer ölphase
EP2287304A1 (de) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Neuartige Behandlung von Patienten nach Stentimplantation oder Ballondilatation und neuartige Arzneimittel eluierende Stents
EP2467380B1 (de) 2009-08-18 2016-11-30 Ventirx Pharmaceuticals, Inc. Substituierte benzoazepine als toll-like-rezeptor-modulatoren
CN105669553A (zh) 2009-08-18 2016-06-15 文蒂雷克斯药品公司 作为toll样受体调节剂的取代的苯并氮杂*
EP3323423B1 (de) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
JP2013520521A (ja) 2009-11-09 2013-06-06 ゼノポート，インコーポレーテッド レボドパプロドラッグの医薬組成物及び経口剤形並びに使用方法
NZ600256A (en) 2009-12-02 2014-05-30 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
US20110293585A1 (en) 2010-04-21 2011-12-01 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
KR20130107203A (ko) 2010-05-04 2013-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
MX2012012991A (es) 2010-05-11 2012-11-30 Cima Labs Inc Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
CN103153994B (zh) 2010-05-24 2016-02-10 罗切斯特大学 双环杂芳基激酶抑制剂及使用方法
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
NZ612285A (en) 2010-12-22 2015-09-25 Bayer Ip Gmbh Enhanced immune response in bovine species
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP3207930A1 (de) 2011-01-12 2017-08-23 VentiRx Pharmaceuticals, Inc. Substituierte benzoazepine als toll-like-rezeptor-modulatoren
CN106749023A (zh) 2011-01-12 2017-05-31 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
MY165507A (en) 2011-02-03 2018-03-28 Mirna Therapeutics Inc Synthetic mimics of mir-34
EP2670849A1 (de) 2011-02-03 2013-12-11 Mirna Therapeutics, Inc. Synthetische mimetika von mir-124
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP6133790B2 (ja) 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
CN105148285B (zh) 2011-04-21 2019-02-12 塔夫茨大学信托人 用于活性试剂稳定化的方法和组合物
US9353115B2 (en) 2011-06-01 2016-05-31 Janus Biotherapeutics, Inc. Immune system modulators
CA2837227C (en) 2011-06-01 2022-05-10 Janus Biotherapeutics, Inc. Novel immune system modulators
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
CA2842321C (en) 2011-07-18 2022-05-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013013061A1 (en) 2011-07-19 2013-01-24 University Of Vermont And State Agricultural College Methods and compounds for treating cancer
WO2013020044A1 (en) 2011-08-03 2013-02-07 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Treatment of fibrosis using microrna-19b
AU2012318694B2 (en) 2011-10-04 2016-12-22 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
US9173884B2 (en) 2011-11-30 2015-11-03 Trustees Of Boston College Inhibitors of phosphodiesterase 11 (PDE11)
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
JP2013119550A (ja) 2011-12-08 2013-06-17 Medicinova Inc 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法
EP2794657B1 (de) 2011-12-19 2017-10-11 Xoma (Us) Llc Verfahren zur behandlung von akne
JP6684490B2 (ja) 2012-01-09 2020-04-22 ザ・スクリップス・リサーチ・インスティテュート 超長相補性決定領域及びその使用
AU2013208007A1 (en) 2012-01-09 2014-07-31 The Scripps Research Institute Humanized antibodies with ultralong CDR3
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN110812470A (zh) 2012-07-11 2020-02-21 佛蒙特大学及州农业学院 用于代谢调节的方法和组合物
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
US8962020B2 (en) * 2012-07-26 2015-02-24 Glycadia Inc. Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
US9636376B2 (en) * 2012-09-11 2017-05-02 Innopharma, Inc. Stable compositions of peptide epoxy ketones
EP3795694A3 (de) 2012-10-02 2021-06-23 The General Hospital Corporation d/b/a Massachusetts General Hospital Verfahren für mit dem dna-erfassungspfad assoziierten leiden
WO2014055941A2 (en) 2012-10-04 2014-04-10 Pappalardo Juan Sabastian Compounds and methods for targeted immune system delivery
WO2014074805A1 (en) 2012-11-08 2014-05-15 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
WO2014085795A1 (en) 2012-11-30 2014-06-05 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
US9872851B2 (en) 2012-12-12 2018-01-23 The Charlotte-Mecklenburg Hospital Authority Methods of treating portal hypertension
US9750718B2 (en) 2012-12-12 2017-09-05 The Charlotte-Mecklenburg Hospital Authority Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity
JP6457482B2 (ja) 2013-03-15 2019-01-23 トラスティーズ オブ タフツ カレッジ 低分子量絹組成物および絹組成物の安定化
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
EP3981388A1 (de) 2013-03-21 2022-04-13 Eupraxia Pharmaceuticals USA LLC Injizierbare zusammensetzung mit verzögerter freisetzung und verfahren zur verwendung für die behandlung von entzündungen in gelenken und damit einhergehendem schmerz
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
ES2843511T3 (es) 2013-07-25 2021-07-19 Medicinova Inc Métodos para reducir las concentraciones en sangre de triglicéridos, colesterol total y lipoproteínas de baja densidad
EP3043824B1 (de) 2013-09-13 2022-07-06 The Scripps Research Institute Modifizierte therapeutische mittel und zusammensetzungen daraus
AU2014337385B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Chimeric antigen receptor T cell switches and uses thereof
EP3057994B1 (de) 2013-10-15 2020-09-23 The Scripps Research Institute Chimäre peptidische antigenrezeptor-t-zell-schalter und verwendungen davon
EP3063171B1 (de) 2013-11-01 2019-07-24 University Of Oslo Albuminvarianten und verwendungen davon
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082797A4 (de) 2013-12-18 2017-12-13 The California Institute for Biomedical Research Modifizierte therapeutika, geheftete peptidlipidkonjugate und zusammensetzungen davon
EP3083658B1 (de) 2013-12-18 2019-05-08 President and Fellows of Harvard College Detektion gram-positiver bakterien mit crp
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095460A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum
WO2015128461A1 (en) 2014-02-28 2015-09-03 Bayer Animal Health Gmbh Immunostimulatory plasmids
WO2015168255A1 (en) 2014-04-29 2015-11-05 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
WO2015170195A1 (en) * 2014-05-03 2015-11-12 GORREPATI, Navaneeta Krishna Hydrazaline hydrochloride pellets and its preparation method
US20150321989A1 (en) 2014-05-08 2015-11-12 Medicinova, Inc. Method of treating idiopathic pulmonary fibrosis
US9346754B2 (en) 2014-05-08 2016-05-24 Medicinova, Inc. Method of treating advanced non-alcoholic steatohepatitis
PL3140269T3 (pl) 2014-05-09 2024-03-11 Yale University Cząstki pokryte hiperrozgałęzionym poliglicerolem oraz sposoby ich wytwarzania i zastosowania
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
CN106470678A (zh) 2014-06-02 2017-03-01 美迪诺亚公司 抑制或治疗纤维化的方法
EP3398948A3 (de) 2014-08-22 2018-12-05 Janus Biotherapeutics, Inc. 2,4,6,7-tetrasubstituierte pteridinverbindungen und verfahren zur synthese und verwendung davon
WO2016036674A1 (en) 2014-09-02 2016-03-10 Bhupinder Singh Deuterated or a non-deuterated molecule and pharmaceutical formulations
JP6678676B2 (ja) * 2014-09-15 2020-04-08 オーファザイム エー／エス アリモクロモル製剤
MX2017003556A (es) 2014-09-19 2017-07-14 Procter & Gamble Formas de dosificacion de fenilefrina de liberacion pulsada.
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10751317B2 (en) 2014-10-08 2020-08-25 Pacific Northwest Research Institute Methods and compositions for increasing the potency of antifungal agents
EP3204039B1 (de) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsionszusammensetzungen zur prävention, unterdrückung oder eliminierung von allergischen und entzündlichen erkrankungen
CA3002137A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CA2966801A1 (en) 2014-11-07 2016-05-12 Sigmoid Pharma Limited Compositions comprising cyclosporin
US10227285B2 (en) 2014-11-14 2019-03-12 Gemphire Therapeutics Inc. Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers
JP6827924B2 (ja) 2014-11-26 2021-02-10 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． イブジラスト及びリルゾールの組み合わせを含む医薬および組成物
MA41152A (fr) * 2014-12-12 2017-10-17 Johnson & Johnson Consumer Inc Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
EP3234193B1 (de) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molekulare biomarker für krebsimmuntherapie
WO2016130726A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CN107592866A (zh) 2015-02-18 2018-01-16 佛蒙特大学及州农业学院 Mcj激动剂及其用途
CN107530416A (zh) 2015-03-05 2018-01-02 西北大学 非神经侵染的病毒及其用途
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
EP3283113A4 (de) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimierte pne-basierte chimäre t-zell-rezeptor-schalter und verwendungen davon
CA3019311A1 (en) 2015-04-15 2016-10-20 University Of Massachusetts Compositions and methods for xi chromosome reactivation
CR20230191A (es) 2015-05-20 2023-07-06 Dana Farber Cancer Inst Inc NEOANTIGENOS COMPARTIDOS (Div. exp 2017-584)
EP3302354B1 (de) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Systeme zum einsetzen eines implantats
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
JP2018521130A (ja) 2015-07-10 2018-08-02 ユニバーシティ・オブ・バーモント・アンド・ステイト・アグリカルチュラル・カレッジＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｖｅｒｍｏｎｔ Ａｎｄ Ｓｔａｔｅ Ａｇｒｉｃｕｌｔｕｒａｌ Ｃｏｌｌｅｇｅ 薬物性疾患および状態を治療する方法および組成物
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
US10457941B2 (en) 2015-08-20 2019-10-29 ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC bioGUNE Methods and compositions to treat liver diseases and conditions
CA2998745A1 (en) 2015-09-17 2017-03-23 University Of Massachusetts Compositions and methods for modulating fmr1 expression
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
PT3206672T (pt) 2015-10-27 2018-06-20 Eupraxia Pharmaceuticals Inc Formulações de libertação prolongada de anestésicos locais
AU2016348638A1 (en) * 2015-11-06 2018-06-07 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
US20200308590A1 (en) 2016-02-16 2020-10-01 Yale University Compositions and methods for treatment of cystic fibrosis
EP3416494A4 (de) * 2016-02-17 2019-11-13 Corr-Jensen Inc. Retard-vitamine und -mineralstoffe in speiseölen
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
CN109414489B (zh) 2016-04-08 2022-08-16 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体及其用途
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US20190322643A1 (en) 2016-06-29 2019-10-24 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
BR112019000636A2 (pt) * 2016-07-17 2019-04-30 Mapi Pharma Ltd. formas de dosagem de liberação prolongada de pregabalina
SG11201900710YA (en) 2016-07-26 2019-02-27 Bayer Animal Health Gmbh Increased fertility in bovine species
BR112019002538A2 (pt) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
US20190201350A1 (en) * 2016-08-15 2019-07-04 Corr-Jensen Inc. Time release of fat-soluble actives
EP3529268A1 (de) 2016-10-19 2019-08-28 The Scripps Research Institute Chimäre antigenrezeptor-effektorzellen-switches mit humanisierten targeting-einheiten und/oder optimierten chimären antigen-rezeptor-interaktionsdomänen und verwendungen davon
EP3896451A1 (de) 2016-11-07 2021-10-20 University Of Massachusetts Carm1 inhibitoren für fazioskapulohumerale muskeldystrophie
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
EP3574116A1 (de) 2017-01-24 2019-12-04 The Broad Institute, Inc. Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
EP3576726A1 (de) 2017-02-06 2019-12-11 Massachusetts Institute Of Technology Verfahren und produkte in verbindung mit glutaminase-hemmern
US10278930B2 (en) 2017-03-16 2019-05-07 The Procter & Gamble Company Method for relieving sinus congestion
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
US11225512B2 (en) 2017-04-27 2022-01-18 University Of New Hampshire Compositions and methods for ceramide-elevating therapeutic strategies
WO2019014611A2 (en) 2017-07-14 2019-01-17 University Of Massachusetts METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATION
US20220118076A1 (en) 2017-09-07 2022-04-21 University Of Oslo Vaccine molecules
EP3678699A1 (de) 2017-09-07 2020-07-15 University Of Oslo Impfstoffmoleküle
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
EP3773612A4 (de) 2018-03-28 2022-01-12 Herbalife International of America, Inc. Acetylierung von polysacchariden
PT3773537T (pt) 2018-04-19 2022-04-19 Baylor College Medicine Inibidores de stat3
EP3867365A1 (de) 2018-10-19 2021-08-25 Board of Regents, The University of Texas System Gentechnisch hergestellte transposons mit langem interspergiertem element (line) und verwendungsverfahren dafür
US20210393592A1 (en) * 2018-11-02 2021-12-23 Celltrion Inc. Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP3883562A4 (de) 2018-11-21 2022-08-03 Tremeau Pharmaceuticals, Inc. Gereinigte formen von rofecoxib, verfahren zur herstellung und verwendung
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
EP3677693A1 (de) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimäre gentranskripte (tcgts) als krebsbiomarker
US20220175934A1 (en) 2019-03-21 2022-06-09 Mitotherapeutix Llc Multivalent ligand clusters for targeted delivery of therapeutic agents
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
CN115551594A (zh) 2019-10-24 2022-12-30 米诺陶治疗公司 经细胞因子修饰的嵌合抗体及其使用方法
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
MX2022006014A (es) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
EP4107267A1 (de) 2020-02-21 2022-12-28 Mitotherapeutix LLC Zusammensetzungen und verfahren zur hemmung der expression von methylierungsgesteuertem j-protein (mcj)
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
EP4059498A1 (de) 2021-03-16 2022-09-21 Centre Hospitalier Universitaire Vaudois (CHUV) Verfahren und zusammensetzungen zur behandlung von zuständen im zusammenhang mit hypermineralisierung
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
WO2022232321A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
WO2022251464A1 (en) 2021-05-28 2022-12-01 Medicinova, Inc. Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
WO2024039376A1 (en) 2022-08-18 2024-02-22 Elanco Us Inc. Method for improving growth performance in feedlot cattle

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (de) * 1962-12-19
CH434571A (de) * 1966-07-05 1967-04-30 Chemical And Pharmaceutical Pa Verfahren zur Herstellung von Antibiotika mit verlängerter therapeutischer Wirkung
US4000254A (en) * 1966-04-25 1976-12-28 Schmid Laboratories, Inc. Fungimycin compositions
US3623997A (en) * 1966-06-06 1971-11-30 Ncr Co Wall-sealing treatment for minute capsules and minute capsules having walls of sealed polymeric material
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
NL131321C (de) * 1967-05-05
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
IT1115596B (it) * 1978-03-13 1986-02-03 Bayer Italia Spa Metodo per la preparazione di microgranuli gastoresistenti ed enterosolubili di sostanze farmaceutiche,in particolare di sostanze proteiche e microgranuli preparati con detto metodo
JPS5545601A (en) * 1978-09-26 1980-03-31 Toyo Jozo Co Ltd Long-acting cephalexin and its preparation
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
IE48715B1 (en) * 1978-12-22 1985-05-01 Elan Corp Plc New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
ATE10582T1 (de) * 1981-01-22 1984-12-15 Capsugel A.G. Verfahren zur herstellung pharmazeutischer, darmloeslicher kapseln.
GB2098867B (en) * 1981-05-21 1984-10-24 Wyeth John & Brother Ltd Sustained release pharmaceutical composition
JPS5826816A (ja) * 1981-08-11 1983-02-17 Teisan Seiyaku Kk 球形顆粒からなる持続性複合顆粒剤
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
IE53703B1 (en) * 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
US4501018A (en) * 1983-07-05 1985-02-19 Motorola, Inc. Simplex transceiver employing a common piezoelectric element for transmitting and receiving
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
DE3333639A1 (de) * 1983-09-17 1985-03-28 Dynamit Nobel Ag Zubereitung von nitroestern fuer die koronartherapie
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
US4917899A (en) * 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
GB2159715B (en) * 1984-06-04 1988-05-05 Sterwin Ag Pharmaceutical composition in sustained release unit dose form and process for its preparation
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
JPS6327424A (ja) * 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
JPH0780754B2 (ja) * 1986-08-06 1995-08-30 エーザイ株式会社 多顆粒型持続性錠剤
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
GB8702411D0 (en) * 1987-02-03 1987-03-11 Zyma Sa Swellable pellets
DK173505B1 (da) * 1987-02-20 2001-01-15 Pharmatec Internat S R L Fremgangsmåde til fremstilling af en diltiazempellet med langsom afgivelse og anvendelse af således fremstillede pelleter t
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US4971805A (en) * 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same

Also Published As

Publication number Publication date
AU635021B2 (en) 1993-03-11
CA2016039A1 (en) 1990-11-05
DE69022876T2 (de) 1996-05-02
US5133974A (en) 1992-07-28
EP0396425A2 (de) 1990-11-07
ES2080796T5 (es) 1999-05-16
DE69022876T3 (de) 1999-06-17
EP0396425B1 (de) 1995-10-11
US5445829A (en) 1995-08-29
ES2080796T3 (es) 1996-02-16
EP0396425B2 (de) 1998-12-30
AU5470390A (en) 1990-11-08
ATE128863T1 (de) 1995-10-15
CA2016039C (en) 2001-07-17
EP0396425A3 (de) 1992-11-19

Similar Documents

Publication Publication Date Title
DE69022876T2 (de) Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe.
AU6770490A (en) Solid pharmaceutical compositions containing cimetidine
KR880010758A (ko) 서방성 제제
CA2031150A1 (en) Sustained-release drug dosage units
DE69217711D1 (de) Auf der gastrointestinale Mukosa klebenden Matrizen oder Überzugmitteln enthaltende pharmazeutische Zubereitung
DE3581819D1 (de) Pyridazinamine wirksam gegen viren.
DK205889D0 (da) Vandbaseret farmaceutisk overtraeksmateriale til doseringsformer
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
ATE191144T1 (de) Nifitepin enthaltende arzneimittel und verfahren
ATE133333T1 (de) Pharmazeutische zubereitung mit verzögerter wirkstoffreigabe und verfahren zur herstellung derselben
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
ATE158172T1 (de) Pulverförmige pharmazeutische zusammensetzung
JPS57183714A (en) Medicinal pharmaceutical
DE69416034D1 (de) Pharmazeutische Zubereitung zur rektalen Verabreichung von pharmakologisch wirksamen Verbindungen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings